Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications

Clinical Cardiology

Volumn 20, Issue 5, 1997, Pages 433-440

  Schneider, David J ^a   Sobel, Burton E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

atherosclerosis; dysinsulinemia; hyperglycemia; hyperlipidemia; insulin resistance; proinsulin; restenosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; PROBUCOL; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TOLAZAMIDE; TOLBUTAMIDE;

ANGIOPLASTY; ANTICOAGULATION; CORONARY ARTERY DISEASE; DRUG EFFICACY; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; TREATMENT PLANNING;

EID: 0030896913     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960200506     Document Type: Review

References (90)

1. Helms RB: Implications of population growth on prevalence of diabetes. A look at the future. Diabetes Care 1992;15(suppl 1):6-9
2. Porte D: β-cells in type II diabetes mellitus. Diabetes 1991;40:166-180
3. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909-915
4. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702
5. Given BD, Cohen RM, Shoelson SE, Frank BH, Rubenstein AH, Tager HS: Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest 1985;76:1398-1405
6. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS: The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990;33:532-537
7. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN: Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989;260:535-541
8. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989;i:293-295
9. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L: Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988;31:793-805
10. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
11. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;31:874-882
12. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990;82:27-36
13. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225
14. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED: Coronary artery disease and coronary artery bypass grafting in diabetic subjects aged >65 years [report from the coronary artery surgery study (CASS) registry]. Am J Cardiol 1994;74:334-339
15. Aronson D, Bloomgarden Z, Rayfield EJ: Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996;27:528-535
16. Kannel WB, D' Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience. Am Heart J 1990;120:672-676
17. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989;2:419-423
18. Singer P, Godicke W, Voigt S, Hajdu I, Weiss M: Postprandial hyperinsulinemia in patients with mild essential hypertension. Hypertension 1985;7:182-186
19. DeFronzo RA: Insulin secretion, insulin resistance, and obesity. Int J Obes 1982;6(S1):73-82
20. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Chetrit A, Fuchs Z: Hyperinsulinemia: A link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75:809-817
21. Fontbonne A, Tchobroutsky G, Eschwege E, Richard JL, Claude JR, Rosselin GE: Coronary heart disease mortality risk: Plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris prospective study. Int J Obes 1988;12:557-565
22. Pyorala K, Savolainen E, Kaukola S, Haapakoski J: Plasma insulin as coronary heart disease risk factor: Relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study Population. Acta Med Scand 1985;701(suppl):38-52
23. Cullen K, Stenhouse NS, Wearne KL, Welborn TA: Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia-13-year study. J Chronic Dis 1983;36:371-377
24. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1225-1230
25. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607
26. Kolterman OG, Gray RS, Griffin J, Insel BJ, Scarlett JA, Olefsky JM: Receptor and post-receptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest 1981;68:957-969
27. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-213
28. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D: Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in non-diabetic and non-insulin-dependent diabetic subjects. J Clin Invest 1984;74:1238-1246
29. Kissebah AH, Alfarsi S, Adams PW, Wynn V: Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridemia in man. Diabetologia 1976;12:563-571
30. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85:37-45
31. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D: Nonenzymatic glucosylation of low-density lipoprotein alters its biological activity. Diabetes 1982;31:283-291
32. Dejager S, Bruckert E, Chapman MJ: Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combine hyperlipidemia. J Lipid Res 1993;34:295-308
33. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D: Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702
34. Given BD, Cohen RM, Shoelson SE, Frank BH, Rubenstein AH, Tager HS: Biochemical and clinical implications of proinsulin conversion intermediates. J Clin Invest 1985;76:1398-1405
35. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS: The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990;33:532-537
36. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP, Luzio SD, Owens DR, Schneider AE, Siddle K, Temple RC, Hales CN: Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. Biochem J 1989;260:535-541
37. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN: Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989;i:293-295
38. Ross R: The pathogenesis of atheroersclerosis: A perspective for the 1990s. Nature 1993;362:801-809
39. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992;89:507-511
40. Majack RA, Cook SC, Bornstein P: Control of smooth muscle cell growth by components of the extracellular matrix: Autocrine role for thrombospondin. Proc Natl Acad Sci USA 1986;83:9050-9054
41. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B: JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 1992;70:314-325
42. Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD: Hormone-like activity of human thrombin. Ann NY Acad Sci 1986;485:335-348
43. Naito M, Hayashi T, Kuzuya M, Funaki C, Asai K, Kuzuya F: Effects of fibrinogen and fibrin on the migration of vascular smooth muscle cells in vitro. Atherosclerosis 1990;83:9-14
44. Seigneur M, Dufourcq P, Conri C, Constans J, Mercie P, Pruvost A, Amiral J, Midy D, Baste JC, Boisseau MR: Levels of plasma thrombomodulin are increased in atheromatous arterial disease. Thrombos Res 1993;71:423-431
45. Rabbani LE, Loscalzo J: Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994;105:1-7
46. Asada Y, Hayashi T, Tanimura N, Kisanuki A, Sumiyoshi A: Replication of endothelial cells and smooth muscle cells induced in vivo by hypercholesterolaemia and materials released from platelet-rich white thrombus. J Path 1992;166:69-75
47. Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767-1773
48. Brownlee M: Glycation and diabetic complications. Diabetes 1994;43:836-841
49. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991;87:1643-1648
50. Cagliero E, Roth T, Roy S, Lorenzi M: Characteristics and mechanisms of high-glucose-induced overexpression of basement membrane components in cultured human endothelial cells. Diabetes 1991;40:102-110
51. Lyons TJ, Lopes-Virella MF, Baystle JW: Glycation, oxidation, and glyoxidation in the pathogenesis of atherosclerosis in diabetes. Mod Med 1993;61:(suppl 2)4-8
52. Vlassara H: Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 1994;124:19-30
53. Bucala R, Makita Z, Zoschinsky T, Cerami A, Vlassara H: Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993;90:6434-6438
54. Ramirez LC, Arauz-Pacheco C, Lackner C, Albright G, Adams BV, Raskin P: Lipoprotein (a) levels in diabetes mellitus: Relationship to metabolic control. Ann Intern Med 1992;117:42-47
55. Sowers JR, Standley PR, Ram JL, Jacober S: Hyperinsulinemia, insulin resistance, and hyperglycemia: Contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens 1993;6:260S-270S
56. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994;43:104-109
57. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D: Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986;35:250-253
58. Auwerx J, Bouillon R, Collen D, Geboers J: Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988;8:68-72
59. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U: Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990;39:1044-1048
60. Jansson JH, Johansson B, Boman K, Nilsson TK: Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. J Intern Med 1991;229:309-316
61. Mehta J, Mehta P, Lawson D, Saldeen T: Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-268
62. Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991;88:9959-9963
63. Fattal PG, Schneider DJ, Sobel BE, Billadello JJ: Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992;267:12412-12415
64. Nordt TK, Schneider DJ, Sobel BE: Augmentation of synthesis of plasminogen activator inhibitor type-1 (PAI-1) by precursors of insulin: A potential risk factor for vascular disease. Circulation 1994;89:321-330
65. Schneider DJ, Nordt TK, Sobel BE: Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992;41:890-895
66. Alessi MC, Juhan-Vague I, Kooistra T, DeClerck PJ, Collen D: Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemostas 1988;60:491-494
67. Kooistra T, Bosma PJ, Tons HAM, Van Den Berg AP, Meyer P, Princen HMG: Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemostas 1989;62:723-728
68. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI: Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-2637
69. Chapman HA Jr, Stone OL: Co-operation between plasmin and elastase degradation by intact murine macrophages. Biochem J 1989;222:721-725
70. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EK, Metcalf RL, Testuz J, Sordat B: Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA 1990;87:6939-6943
71. Chapman HA Jr, Reilly JJ Jr, Kobzik L: Role of plasminogen activator in degradation of extracellular matrix protein by live human alveolar macrophages. Am Rev Respir Dis 1988;137:412-419
72. Pasi KJ, Enayat MS, Horrocks PM, Wright AD, Hill FG: Qualitative and quantitative abnormalities in von Willebrand antigen in patients with diabetes mellitus. Thromb Res 1990;59:581-591
73. Brownlee M, Vlassara H, Cerami A: Inhibition of heparin-catalyzed human antithrombin III activity by nonenzymatic glycosylation. Diabetes 1984;33:532-535
74. Hamet P, Skuherska R, Pang SC, Tremblay J: Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985; 7(suppl II):II135-II142
75. Marcus ML, Harrison DG, Chilian WM, Koyanagi S, Inou T, Tomaneck RJ, Martins JB, Eastham CL, Hiratzka LF: Alterations in the coronary ciruclation in the hypertrophied ventricles. Circulation 1987;75(suppl I):119-125
76. Assmann G, Schulte H: The prospective cardiovascular Münster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713-1724
77. The National High Blood Pressure Education Program Working Group: National High Blood Pressure Education Program Working Group Report on hypertension in diabetes. Hypertension 1994;23:145-158
78. Orth S, Nowicki M, Wiecek A, Ritz E: Nephroprotective effect of ACE inhibitors. Drugs 1993;46(suppl 2):189-196
79. Sowers JR, Epstein M: Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: An update. Hypertension 1995;26:869-879
80. Hughes TA, Clements RS, Fairclough PK: Effects of insulin therapy on lipoproteins in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis 1987;67:105-114
81. Scandinavian Simvastatin Survival Study: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
82. National Cholesterol Education Program (NCEP) Expert Panel: Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II).J Am Med Assoc 1993;269:3015-3023
83. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970;19(suppl 2):747-830
84. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-554
85. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549
86. Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994;17:561-566
87. Toeller M: α-Glucosidase inhibitors in diabetes: Efficacy in NIDDM subjects. Eur J Clin Invest 1994;24(suppl 3):31-35
88. Whitcomb RW, Saltiel AR: Thiazolidinediones. Exp Opin Invest Drugs 1995;4:1299-1309
89. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvements in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193
90. Ogihara T, Rakugi H, Ikegami H, Mikamo H, Masuo K: Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-320